Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
SYN's Cash to Debt is ranked higher than
93% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. SYN: No Debt )
Ranked among companies with meaningful Cash to Debt only.
SYN' s Cash to Debt Range Over the Past 10 Years
Min: 0.03  Med: 10000.00 Max: No Debt
Current: No Debt
Interest Coverage No Debt
SYN's Interest Coverage is ranked higher than
91% of the 385 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. SYN: No Debt )
Ranked among companies with meaningful Interest Coverage only.
SYN' s Interest Coverage Range Over the Past 10 Years
Min: 9999.99  Med: 10000.00 Max: 9999.99
Current: No Debt
F-Score: 2
Z-Score: -2.57
M-Score: -9.51
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
ROE (%) -604.29
SYN's ROE (%) is ranked lower than
97% of the 856 Companies
in the Global Biotechnology industry.

( Industry Median: -30.96 vs. SYN: -604.29 )
Ranked among companies with meaningful ROE (%) only.
SYN' s ROE (%) Range Over the Past 10 Years
Min: -341.6  Med: -120.46 Max: -48.04
Current: -604.29
-341.6
-48.04
ROA (%) -185.05
SYN's ROA (%) is ranked lower than
94% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. SYN: -185.05 )
Ranked among companies with meaningful ROA (%) only.
SYN' s ROA (%) Range Over the Past 10 Years
Min: -174.99  Med: -79.33 Max: -41.8
Current: -185.05
-174.99
-41.8
ROC (Joel Greenblatt) (%) -16740.20
SYN's ROC (Joel Greenblatt) (%) is ranked lower than
91% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. SYN: -16740.20 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
SYN' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -14661.9  Med: -915.08 Max: -112.64
Current: -16740.2
-14661.9
-112.64
EBITDA Growth (3Y)(%) 0.90
SYN's EBITDA Growth (3Y)(%) is ranked higher than
51% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. SYN: 0.90 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
SYN' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 101.3
Current: 0.9
0
101.3
EPS Growth (3Y)(%) 2.70
SYN's EPS Growth (3Y)(%) is ranked higher than
59% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. SYN: 2.70 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
SYN' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 65.1
Current: 2.7
0
65.1
» SYN's 10-Y Financials

Financials (Next Earnings Date: 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2014

SYN Guru Trades in Q4 2014

Chuck Royce Sold Out
» More
Q3 2015

SYN Guru Trades in Q3 2015

Ken Fisher 10,500 sh (New)
» More
Q4 2015

SYN Guru Trades in Q4 2015

Ken Fisher 10,500 sh (unchged)
» More
Q1 2016

SYN Guru Trades in Q1 2016

Ken Fisher 10,500 sh (unchged)
» More
» Details

Insider Trades

Latest Guru Trades with SYN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 11.28
SYN's P/B is ranked lower than
87% of the 842 Companies
in the Global Biotechnology industry.

( Industry Median: 3.38 vs. SYN: 11.28 )
Ranked among companies with meaningful P/B only.
SYN' s P/B Range Over the Past 10 Years
Min: 1.67  Med: 5.82 Max: 14.14
Current: 11.28
1.67
14.14
Current Ratio 1.95
SYN's Current Ratio is ranked lower than
77% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. SYN: 1.95 )
Ranked among companies with meaningful Current Ratio only.
SYN' s Current Ratio Range Over the Past 10 Years
Min: 0.11  Med: 3.57 Max: 31.55
Current: 1.95
0.11
31.55
Quick Ratio 1.95
SYN's Quick Ratio is ranked lower than
73% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. SYN: 1.95 )
Ranked among companies with meaningful Quick Ratio only.
SYN' s Quick Ratio Range Over the Past 10 Years
Min: 0.17  Med: 3.80 Max: 31.55
Current: 1.95
0.17
31.55

Valuation & Return

vs
industry
vs
history
Price/Net Cash 28.57
SYN's Price/Net Cash is ranked lower than
88% of the 495 Companies
in the Global Biotechnology industry.

( Industry Median: 5.42 vs. SYN: 28.57 )
Ranked among companies with meaningful Price/Net Cash only.
SYN' s Price/Net Cash Range Over the Past 10 Years
Min: 0.72  Med: 9.34 Max: 32.71
Current: 28.57
0.72
32.71
Price/Net Current Asset Value 11.76
SYN's Price/Net Current Asset Value is ranked lower than
74% of the 613 Companies
in the Global Biotechnology industry.

( Industry Median: 5.24 vs. SYN: 11.76 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
SYN' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 0.72  Med: 8.07 Max: 25.37
Current: 11.76
0.72
25.37
Price/Tangible Book 11.11
SYN's Price/Tangible Book is ranked lower than
82% of the 776 Companies
in the Global Biotechnology industry.

( Industry Median: 4.11 vs. SYN: 11.11 )
Ranked among companies with meaningful Price/Tangible Book only.
SYN' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.55  Med: 7.08 Max: 24.86
Current: 11.11
0.55
24.86
Earnings Yield (Greenblatt) (%) -25.66
SYN's Earnings Yield (Greenblatt) (%) is ranked lower than
73% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. SYN: -25.66 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
SYN' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -59  Med: 0.00 Max: 0
Current: -25.66
-59
0

More Statistics

Revenue(Mil) $3
EPS $ -0.60
Beta1.42
Short Percentage of Float9.95%
52-Week Range $0.93 - 4.32
Shares Outstanding(Mil)90.83

Analyst Estimate

Dec17 Dec18
Revenue(Mil)
EPS($) -0.70 -0.88
EPS without NRI($) -0.70 -0.88

Business Description

Industry: Biotechnology » Biotechnology
Compare:AMEX:AMPE, LSE:TRX, NAS:CYTR, AMEX:NAVB, XKRX:041910, NAS:PETX » details
Traded in other countries:SFYB.Germany,
Synthetic Biologics Inc was incorporated in 1986 as Sheffield Pharmaceuticals, Inc. The Company is a biotechnology company focused on the development of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and other diseases. Its developing an oral treatment to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome or C-IBS, an oral biologic to protect the gastrointestinal or GI microflora from the effects of intravenous or IV antibiotics for the prevention of Clostridium difficile or C. diff infection, a series of monoclonal antibodies or mAbs for the treatment of Pertussis and Acinetobacter infections, and a biologic targeted at the prevention and treatment of a root cause of a subset of IBS. In addition, it has two legacy programs. Its developing an oral estriol drug for the treatment of relapsing-remitting multiple sclerosis or MS and cognitive dysfunction in MS. It also partnered the development of a treatment for fibromyalgia. Trimesta or oral estriol is being developed as an oral once-daily treatment for relapsing-remitting MS in women. Trimesta is also being developed for the treatment of cognitive dysfunction in female MS patients. This 12-month randomized, double-blind, placebo-controlled Phase II clinical trial is being conducted at UCLA. There are nine FDA-approved therapies for the treatment of relapsing-remitting MS: Betaseron, Rebif, Avonex, Copaxone, Tysabri, Gilenya, Extavia, Aubagio and Tecfidera. Effirma or flupirtine is being developed for the treatment of fibromyalgia by Meda AB. Current FDA-approved therapies for the treatment of C-IBS include AMITIZA or lubiprostone and LINZESS or linaclotide. The Company utilizes contract manufacturing firms to produce its investigational products Trimesta and SYN-004 in accordance with current good manufacturing processes or cGMP guidelines outlined by the FDA. It competes with Actelion Pharmaceuticals, Bayer Health Care, Biogen Idec, Eli Lilly & Co., Genzyme, GlaxoSmithKline Pharmaceuticals, Merck & Co., Pfizer, Novartis, Teva Pharmaceuticals and United Therapeutics, among others. The Company is subject to various government FDA, FTC, CPSC and USDA regulations.
» More Articles for SYN

Headlines

Articles On GuruFocus.com
Synodon Inc. – A Breakthrough Technology For Pipeline Safety Jan 28 2013 

More From Other Websites
Synthetic Biologics to Report First Quarter 2016 Operational Highlights and Financial Results on May... Apr 26 2016
Synthetic Biologics to Report First Quarter 2016 Operational Highlights and Financial Results on May... Apr 26 2016
The Zacks Analyst Blog Highlights: Corcept Therapeutics, Epizyme, Geron and Synthetic Biologics Mar 29 2016
SYNTHETIC BIOLOGICS, INC. Financials Mar 16 2016
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and... Mar 14 2016
Synthetic Biologics reports 4Q loss Mar 10 2016
Synthetic Biologics reports 4Q loss Mar 10 2016
SYNTHETIC BIOLOGICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition,... Mar 10 2016
Synthetic Biologics Reports 2015 Year End Operational Highlights and Financial Results Mar 10 2016
Synthetic Biologics to Present at the 28th Annual ROTH Conference Mar 09 2016
Synthetic Biologics to Report 2015 Year End Results on March 10, 2016 Mar 03 2016
13G Filing: Knoll Capital Management Raises Stake in Synthetic Biologics, Inc. (SYN) Mar 01 2016
Synthetic Biologics Announces Further U.S. Patent Successes Covering SYN-004 Intended for the... Mar 01 2016
Coverage initiated on Synthetic Biologics by FBR Capital Feb 26 2016
Kamich Snips 'Snap-Back' Outook of Canadian Analysts for 6 Bank Stocks Feb 22 2016
Synthetic Biologics Announces the Allowance of Key U.S. Patent Covering SYN-010 Intended for the... Feb 17 2016
Synthetic Biologics to Participate in Fireside Chat at RBC Capital Markets' Global Healthcare... Feb 16 2016
Synthetic Biologics Tanks on Unfavorable Trimesta Data Feb 03 2016
Synthetic Biologics to Present at the 2016 BIO CEO & Investor Conference Feb 03 2016
Synthetic Biologics Crashes Following Disappointing Phase 2 Results Feb 02 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK